SCYNEXIS, Inc. (SCYX)

Market Cap	24.95M
Revenue (ttm)	2.93M
Net Income (ttm)	-25.30M
Shares Out	41.92M
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,727
Open	0.5965
Previous Close	0.5964
Day's Range	0.5816 - 0.6388
52-Week Range	0.5816 - 1.4900
Beta	1.37
Analysts	Strong Buy
Price Target	3.00 (+404.2%)
Earnings Date	Nov 5, 2025

About SCYX

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has lic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 2, 2014
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: SCYX
• Website: https://www.scynexis.com

Analyst Summary

According to one analyst, the rating for SCYX stock is "Strong Buy" and the 12-month stock price target is $3.0.

Price Target

$3.0

(404.20% upside)

Analyst Consensus: Strong Buy